Morgan Stanley lifts Novartis, cuts Roche on diverging growth outlooks

Published 08/08/2025, 11:58
© Reuters.

Investing.com -- Morgan Stanley (NYSE:MS) on Friday issued contrasting ratings changes for two of Switzerland’s pharmaceutical giants, upgrading Novartis AG (SIX:NOVN) while cutting Roche Holding AG (OTC:RHHVF). 

The brokerage cited stronger growth prospects and pipeline potential at Novartis, while pointing to competitive and development headwinds at Roche.

Novartis AG (NYSE:NVS) was raised to “equal-weight” from “underweight,” with its Swiss price target lifted to SFr 100 from SFr 91, and its U.S. target increased to US$123 from US$110. 

The upgrade reflects Morgan Stanley’s view of a higher quality of growth, upside from commercial execution, and strength in the company’s drug pipeline. 

Analysts also flagged the firm’s strong balance sheet and cash flow, which could enable acquisitions to bridge revenue gaps from expected patent expirations in the early 2030s.

In contrast, Roche Holding AG was downgraded to “underweight” from “equal-weight.” Its Swiss price target was reduced to SFr 245 from SFr 286, while the U.S. target was lowered to US$39 from US$44. 

Morgan Stanley cited intensifying competition, setbacks in new product launches, and high-risk pipeline readouts as key factors behind the downgrade. 

The brokerage also noted that pipeline momentum is expected to remain sluggish into 2026. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.